Haematologica (Jul 2016)

Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family

  • Anand Pathak,
  • Katja Seipel,
  • Alexander Pemov,
  • Ramita Dewan,
  • Christina Brown,
  • Sarangan Ravichandran,
  • Brian T. Luke,
  • Michael Malasky,
  • Shalabh Suman,
  • Meredith Yeager,
  • NCI DCEG Cancer Genomics Research Laboratory,
  • NCI DCEG Cancer Sequencing Working Group,
  • Richard A. Gatti,
  • Neil E. Caporaso,
  • John J. Mulvihill,
  • Lynn R. Goldin,
  • Thomas Pabst,
  • Mary L. McMaster,
  • Douglas R. Stewart

DOI
https://doi.org/10.3324/haematol.2015.130799
Journal volume & issue
Vol. 101, no. 7

Abstract

Read online

Familial acute myeloid leukemia is rare and linked to germline mutations in RUNX1, GATA2 or CCAAT/enhancer binding protein-α (CEBPA). We re-evaluated a large family with acute myeloid leukemia originally seen at NIH in 1969. We used whole exome sequencing to study this family, and conducted in silico bioinformatics analysis, protein structural modeling and laboratory experiments to assess the impact of the identified CEBPA Q311P mutation. Unlike most previously identified germline mutations in CEBPA, which were N-terminal frameshift mutations, we identified a novel Q311P variant that was located in the C-terminal bZip domain of C/EBPα. Protein structural modeling suggested that the Q311P mutation alters the ability of the CEBPA dimer to bind DNA. Electrophoretic mobility shift assays showed that the Q311P mu-tant had attenuated binding to DNA, as predicted by the protein modeling. Consistent with these findings, we found that the Q311P mutation has reduced transactivation, consistent with a loss-of-function mutation. From 45 years of follow up, we observed incomplete penetrance (46%) of CEBPA Q311P. This study of a large multi-generational pedigree reveals that a germline mutation in the C-terminal bZip domain can alter the ability of C/EBP-α to bind DNA and reduces transactivation, leading to acute myeloid leukemia.